Revolution Medicines (NASDAQ:RVMD) & Quince Therapeutics (NASDAQ:QNCX) Head-To-Head Review

Revolution Medicines (NASDAQ:RVMD) and Quince Therapeutics (NASDAQ:QNCX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Revolution Medicines and Quince Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	0	0	12	1	3.08
Quince Therapeutics	0	0	5	2	3.29

Revolution Medicines currently has a consensus price target of $65.23, indicating a potential upside of 107.74%. Quince Therapeutics has a consensus price target of $8.00, indicating a potential upside of 555.74%. Given Quince Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Quince Therapeutics is more favorable than Revolution Medicines.

Earnings & Valuation

This table compares Revolution Medicines and Quince Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$742,000.00	7,867.48	-$436.37 million	($3.57)	-8.80
Quince Therapeutics	N/A	N/A	-$31.39 million	($1.31)	-0.93

Quince Therapeutics has lower revenue, but higher earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 8.0% of Revolution Medicines shares are held by company insiders. Comparatively, 16.8% of Quince Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Revolution Medicines has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500. Comparatively, Quince Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.

Profitability

This table compares Revolution Medicines and Quince Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-33.67%	-30.08%
Quince Therapeutics	N/A	-53.27%	-22.73%

Summary

Quince Therapeutics beats Revolution Medicines on 8 of the 13 factors compared between the two stocks.

About Revolution Medicines

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company’s RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

About Quince Therapeutics

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.